Johannes Bragelmann; Marcel A. Dammert; Felix Dietlein; Johannes M. Heuckmann; Axel Choidas; Stefanie Bohm; Andre´ Richters; Debjit Basu; Verena Tischler; Carina Lorenz; Peter Habenberger; Zhizhou Fang; Sandra Ortiz-Cuaran; Frauke Leenders; Jan Eickhoff; Uwe Koch; Matthaus Getlik; Martin Termathe; Muhammad Sallouh; Zoltan Greff; Zoltan Varga; Hyatt Balke-Want; Christopher A. French; Martin Peifer; H. Christian Reinhardt; László Őrfi; György Kéri; Sascha Ansen; Lukas C. Heukamp; Reinhard Buttner; Daniel Rauh; Bert M. Klebl; Roman K. Thomas; Martin L. Sos
(2017)
Kinase inhibitors represent the backbone of targeted cancer therapy, yet only a limited number of oncogenic drivers are directly druggable. By interrogating the activity of 1,505 kinase inhibitors, we found that ...